Middle East experience from the Asia And Latin America Fracture Observational Study (ALAFOS): Baseline characteristics of postmenopausal women with osteoporosis using teriparatide.
Adult
Aged
Asia
/ epidemiology
Bone Density
Bone Density Conservation Agents
/ therapeutic use
Female
Humans
Latin America
/ epidemiology
Middle East
/ epidemiology
Osteoporosis
/ drug therapy
Osteoporosis, Postmenopausal
/ drug therapy
Postmenopause
Prospective Studies
Quality of Life
Saudi Arabia
Teriparatide
/ therapeutic use
United Arab Emirates
/ epidemiology
Bone mineral density
non-vertebral fracture
observational study
osteoporosis
quality of life
teriparatide
vertebral fracture
Journal
The Journal of international medical research
ISSN: 1473-2300
Titre abrégé: J Int Med Res
Pays: England
ID NLM: 0346411
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
We aimed to describe the baseline clinical characteristics and fracture history of patients taking teriparatide in routine clinical practice in the Middle East (ME) subregional cohort of the Asia and Latin America Fracture Observational Study (ALAFOS). Herein, we report baseline clinical characteristics of patients who were prescribed teriparatide (20 µg/day, subcutaneous injection) in four participant ME countries (Saudi Arabia, United Arab Emirates, Kuwait, and Lebanon). The ME cohort included 707 patients mean (SD) age 69.3 (11.6) years. Mean (SD) bone mineral density (BMD) T-scores at baseline were -3.13 (1.28) for lumbar spine, -2.88 (0.94) for total hip, and -2.65 (1.02) for femoral neck. Osteoporotic fractures after age 40 years were reported in 45.8% (vertebral fracture 14.4%, hip fracture 18.4%) and comorbidities in 57.4% of patients. Before starting teriparatide, 19.9% of patients took other osteoporosis medications. The median (Q1; Q3) EuroQoL 5-Dimension 5-Level visual analog scale score for perceived overall health status was 70 (50; 80). Mean (SD) worst back pain in the previous 24 hours was 4.0 (3.2) using a 10-point numeric rating scale. This analysis indicated that in ME countries, teriparatide is usually prescribed to patients with low BMD and high comorbidities, with prior fractures.
Identifiants
pubmed: 32762404
doi: 10.1177/0300060520940855
pmc: PMC7557781
doi:
Substances chimiques
Bone Density Conservation Agents
0
Teriparatide
10T9CSU89I
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
300060520940855Références
Osteoporos Int. 2006 Dec;17(12):1726-33
pubmed: 16983459
P T. 2018 Feb;43(2):92-104
pubmed: 29386866
Crit Care Med. 2008 Sep;36(9):2667-74
pubmed: 18679112
Lancet. 1999 Mar 13;353(9156):878-82
pubmed: 10093980
Calcif Tissue Int. 2016 Sep;99(3):259-71
pubmed: 27137783
J Bone Miner Res. 2003 Nov;18(11):1932-41
pubmed: 14606504
Eur J Rheumatol. 2017 Mar;4(1):46-56
pubmed: 28293453
J Musculoskelet Neuronal Interact. 2007 Apr-Jun;7(2):131-43
pubmed: 17627082
N Engl J Med. 2001 May 10;344(19):1434-41
pubmed: 11346808
J Clin Endocrinol Metab. 2014 Jan;99(1):97-100
pubmed: 24203068
Bone. 2002 Jul;31(1):32-6
pubmed: 12110409
Arch Osteoporos. 2018 Jan 24;13(1):6
pubmed: 29368309
Osteoporos Int. 1992 Nov;2(6):285-9
pubmed: 1421796
Transfusion. 2007 Aug;47(8):1468-80
pubmed: 17655591
Basic Clin Pharmacol Toxicol. 2004 Jun;94(6):260-70
pubmed: 15228497
BMC Musculoskelet Disord. 2014 Jan 08;15:5
pubmed: 24400907
J Community Health. 2013 Dec;38(6):1098-105
pubmed: 23780302
Healthcare (Basel). 2016 Jun 29;4(3):
pubmed: 27417624
Lancet. 2018 Jan 20;391(10117):230-240
pubmed: 29129436
Arch Intern Med. 2004 Oct 11;164(18):2024-30
pubmed: 15477438
Daru. 2017 Feb 7;25(1):2
pubmed: 28173850
Bone. 2012 Mar;50(3):713-22
pubmed: 22178778
Osteoporos Int. 2017 May;28(5):1531-1542
pubmed: 28168409
Osteoporos Int. 2005 May;16(5):447-55
pubmed: 15609073
Menopause. 2015 Sep;22(9):1012-20
pubmed: 25608272
World J Orthop. 2016 Mar 18;7(3):171-81
pubmed: 27004165
J Bone Miner Res. 2005 Feb;20(2):177-84
pubmed: 15647810
Orthop Traumatol Surg Res. 2013 Oct;99(6):675-80
pubmed: 24007698
Osteoporos Int. 2015 Sep;26(9):2243-8
pubmed: 26018089
BMC Musculoskelet Disord. 2018 May 14;19(1):144
pubmed: 29759066
Saudi Med J. 2004 Nov;25(11):1623-5
pubmed: 15573189
J Osteoporos. 2010 Aug 02;2010:757102
pubmed: 20981334
Calcif Tissue Int. 2019 Feb;104(2):193-200
pubmed: 30343436
J Steroid Biochem Mol Biol. 2014 Jul;142:155-70
pubmed: 24176761
Osteoporos Int. 2013 Aug;24(8):2309-17
pubmed: 23404615
Curr Med Res Opin. 2019 Jun;35(6):1041-1049
pubmed: 30474449
Int J Epidemiol. 1998 Oct;27(5):860-5
pubmed: 9839744
Clin Interv Aging. 2016 Jul 06;11:913-25
pubmed: 27462147
J Clin Densitom. 2004 Winter;7(4):368-75
pubmed: 15618596
Osteoporos Int. 2005 Jan;16(1):43-55
pubmed: 15167986
Ann Saudi Med. 2015 Jan-Feb;35(1):1-12
pubmed: 26142931
Mediterr J Rheumatol. 2017 Mar 28;28(1):27-32
pubmed: 32185251
Clin Interv Aging. 2007;2(4):499-507
pubmed: 18225450
N Engl J Med. 2006 May 25;354(21):2250-61
pubmed: 16723616
Curr Med Res Opin. 2008 Feb;24(2):377-84
pubmed: 18154690
J Clin Transl Endocrinol. 2018 Oct 03;14:19-24
pubmed: 30310769
Curr Med Res Opin. 2017 Nov;33(11):2049-2056
pubmed: 28699789
Saudi Med J. 2015 Oct;36(10):1149-50
pubmed: 26446322
Indian J Endocrinol Metab. 2015 Jul-Aug;19(4):483-90
pubmed: 26180763
Saudi Med J. 2003 Sep;24(9):953-6
pubmed: 12973476